Laws and Regulations Promulgated to Give Effect to the Provisions of the International Treaties on Narcotic Drugs and Psychotropic Substances

Total Page:16

File Type:pdf, Size:1020Kb

Laws and Regulations Promulgated to Give Effect to the Provisions of the International Treaties on Narcotic Drugs and Psychotropic Substances E/NL. 1977/26-28 20 March 1979 UNITED NATIONS ENGLISH AND SPANISH ONLY LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE INTERNATIONAL TREATIES ON NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES CHILE Communicated by the Government of Chile NOTE BY THE SECRETARY GENERAL - In accordance with the relevant Articles of the International Treaties on Narcotic Drugs and Psychotropic Substances, the Secretary-General has the honour to communicate the following legislative texts. INDEX Page E/NL.1977/26 Regulation No. 4 on Dependence-producing Pharmaceutical Products, 2 January 1970 E/NTJ.1977/27 Order No. 90 of 4 February 1970 - Schedule of products subject to control under the Regulations on Dependence-producing Pharmaceutical Products. 5 E/NLol977/28 Order No. 92 of 19 January 1976 13 Official Gazette No. 27.554 E/NL,1977/26 24 January 1970 Recovery of Health Division Pharmaceutical Section REGULATION NO. 4 ON DEPENDENCE-PRODUCING PHARMACEUTICAL PRODUCTS Santiago, 2 January 1970 Considering the information furnished by the National Health Service in Circular No. 19.892 of 1 October 1969; the reports, recommendations and agreement of the United Nations specialized agencies concerning the harmful effects of abuse of dependence- producing drugs; the provisions of articles 2 and 107 of the Health Code; and the authority conferred on the undersigned by article 72 (2) of the Constitution of Chile, IT IS HEREBY DECREED AS FOLLOWS: The "REGULATIONS ON DEPENDENCE PRODUCING PHARMACEUTICAL PRODUCTS" set out below are adopted: Article 1. The production, manufacture, extraction, preparation, import, export, distribution, possession or ownership, removal for whatever reason, transit, transport and use of hypnotic agents, amphetamines and other stimulants of the central nervous system, meprobamates and all other dependence-producing drugs, shall be subject to the norms contained in these Regulations. - 2 - The National Health Service shall establish by means of an internal order the schedule of pharmaceutical products referred to in the above paragraph, and shall publish it in the "Official Gazette»" Article 20 The production, manufacture, extraction, preparation, import, export, distribution, transit and transport over the national territory of dependence-producing drugs shall be subject to authorization from the National Health Service. In the case of importation of the said products, it is the responsibility of the said Service to issue an import authorization for each consignment. Article 3« In the case of new dependence-producing drugs, the authorization referred to in the previous article is conditional upon a prior favourable report of the Commission of the Chilean Pharmacopoeia in accordance with the provisions of article 102 of the Health Code„ Article 4« Production laboratories, drug dispensaries and pharmacies shall keep a "Register of dependence-producing drugs", open to inspection by the National Health Service, and the following information shall be entered on separate folios for each of the products: incoming stock: (a) Date; (b) Quantity; (c) Number and date of the authorization issued by the National Health Service; (d) Number of the invoice, customs clearance slip or other document specifying the supplier, where applicable, and particulars concerning the supplier; (e) Serial number where appropriate. Outgoing stock: (a) Date; (b) Quantity; (c) Name of drug used and serial number where appropriate; (d) Number of the invoice, customs clearance slip or other internal control document of the establishment; (e) Prescription registration number, if any; (f) Particulars of the addressee, and (g) Particulars of the doctor or dentist in the case of prescriptions. The vouchers for incoming and outgoing of products shall be filed separately and in proper order. - 3 - Article 5. Drugs may not be packed in containers of less than 10 or more than 50 units (pills, tablets, dragees or capsules), with the exception of clinical packs for medical care institutions, which may contain more,, The packages shall be labelled as follows: "To be sold on medical prescription"; "For use under medical supervision", and in black letters on a white background: "Subject to dependence-producing drugs control." The labels shall also carry a five-pointed green starc Article 6„ Natural or juridical persons importing, processing or distributing the drugs referred to in these Regulations may only sell them to drug dispensaries, pharmacies, clinics, hospitals and medical care establishments whether public or private, subject to the written request of the pharmaceutical chemist in charge or the Chief Medical Officer, as the case may be. All sales made by the said natural or juridical persons to drug dispensaries, pharmacies, and medical care establishments, shall be reported to the Directorate-General of the National Health Service within the first 10 days of the month following the date of the transaction, by dispatch of a copy of the delivery voucher. The delivery voucher must be clearly legible and contain at least the following data: the date, quantity (in figures and letters), and name of the product sold; and particulars concerning the purchaser or consignee, together with his full name or the trade name of the establishment, domicile and place of business. Article 7<> Iti medical care establishments, whether public or private, including those serving the Armed Forces, the Police and the Prisons Service, the drugs referred to in these Regulations prescribed for their patients shall be subject to the provisions of article 4« It is the duty of the Chief Medical Officer of the establishment to ensure that these provisions are respected. Article 8. Without prejudice to the provisions of the preceding article, the pharmaceutical products referred to in the present Regulations may be sold to the public only by pharmacies against a doctor's prescription. Article 9» Prescriptions for these drugs shall contain particulars enabling the practitioner to be identified, including his name and address. The practitioner shall sign the prescription for the drugs, indicating in letters the quantity of each of them and the date on which the prescription was made out, and he shall indicate at the foot of the document, in his own handwriting, his number in the Medical Register. When these pharmaceutical products are prescribed on forms provided by medical care establishments, the practitioner shall proceed as provided in the previous paragraph, indicating in addition his full name and address. Prescriptions shall be valid for only 30 days from the day of issue. No pharmacy may honour a prescription once the time-limit has expired, with the exception of those referred to in the second and third paragraphs of article 10. - 4 - Pharmacies shall file in sequence prescriptions they have filled, duly cancelling them except in the case of those referred to in the second and third paragraphs of article 10. At the request of 'the interested party, the pharmaceutical chemist in charge shall provide a copy of the prescription filled, adding a note to that effect at the foot of the document under his signature„ Article 10. The drugs prescribed in each prescription shall "be dispensed once only, and in the total quantity prescribed. However, in the case of barbiturates used in the treatment of epilepsy, and other drugs used for similar purposes as determined by the National Health Service, the prescription may be split up. The pharmaceutical chemist in charge at the pharmacy shall certify in the prescription the quantity issued, appending his signature and stamp, and shall make a note to that effect in the prescriptions register, with the name of the doctor who made out the prescription and the date thereof. Article 11. Dental surgeons may prescribe hypnotic agents only for direct administration to their patients. The sale of such drugs to the practitioner must be made personally against a prescription which must comply with the same requirements as those set out in article 9 for medical pre scriptions. Article 12. The National Health Service shall indict and penalize the pharmaceutical chemist in charge, and the owner, of any pharmacy who knowingly or maliciously fills a prescription which has been falsified or tampered with, without prejudice to the option of bringing the facts to the notice of the courts. Ih order to safeguard his responsibility, the pharmaceutical chemist in charge may decline to fill prescriptions about whose authenticity and integrity he has doubts; when he does so he shall record in writing on the prescription itself the reasons for his refusal, appending his signature. In the same way he may, if he thinks it advisable to do so, require full particulars concerning the purchaser, making a note to that effect on the document. Article 13. The dependence-producing drugs covered by the provisions of these Regulations shall be subject to the following restrictions: (a) The sale or disposal of such products for whatever reason to persons under 18 years of age is prohibited; (b) Private pharmacies are prohibited from filling medical prescriptions when they are made out on forms issued by medical care establishments, unless the form itself contains a note from the prescribing doctor certifying that the dispensary of the establishment does not have the product in stock, and bearing the doctor's full name, registration number in the Medical Register, and his signature. In the absence of the practitioner who made out the prescription, certification shall be
Recommended publications
  • Sectionpm E] Analytical Кгейг“' Control Radiopharmaceuticals
    section P m e ] Analytical кгейг“' Control i - ¡ Q f Radiopharmaceuticals Proceedings of a Panel Vienna, • ° 7-11 July 1969 INTERNATIONAL ATOMIC ENERGY AGENCY, VIENNA, 1970 ANALYTICAL CONTROL OF RADIOPHARMACEUTICALS The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GREECE .NORWAY ALBANIA GUATEMALA PAKISTAN ALGERIA HAITI PANAMA ARGENTINA HOLY SEE PÂRAGUAY AUSTRALIA HUNGARY PERU AUSTRIA ICELAND PHILIPPINES BELGIUM INDIA POLAND BOLIVIA INDONESIA PORTUGAL BRAZIL IRAN ROMANIA BULGARIA IRAQ' SAUDI ARABIA BURMA IRELAND SENEGAL BYELORUSSIAN SOVIET ISRAEL SIERRA LEONE SOCIALIST REPUBLIC ITALY SINGAPORE CAMBODIA IVORY COAST SOUTH AFRICA CAMEROON JAMAICA SPAIN CANADA JAPAN SUDAN CEYLON JORDAN SWEDEN CHILE KENYA SWITZERLAND CHINA KOREA, REPUBLIC OF SYRIAN ARAB REPUBLIC COLOMBIA KUWAIT THAILAND CONGO, DEMOCRATIC LEBANON TUNISIA REPUBLIC OF LIBERIA TURKEY COSTA RICA LIBYAN ARAB REPUBliC UGANDA CUBA LIECHTENSTEIN UKRAINIAN'SOVIET SOCIALIST CYPRUS LUXEMBOURG REPUBLIC CZECHOSLOVAK SOCIALIST MADAGASCAR UNION OF SOVIET SOCIALIST REPUBLIC MALAYSIA REPUBLICS DENMARK MALI UNITED ARAB REPUBLIC DOMINICAN REPUBLIC MEXICO UNITED KINGDOM OF GREAT ECUADOR MONACO BRITAIN AND NORTHERN EL SALVADOR MOROCCO IRELAND ETHIOPIA NETHERLANDS UNITED STATES OF AMERICA FINLAND NEW ZEALAND URUGUAY FRANCE NICARAGUA VENEZUELA GABON NIGER VIET-NAM GERMANY, FEDERAL REPUBLIC OF NIGERIA YUGOSLAVIA GHANA *• ZAMBIA The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters,
    [Show full text]
  • 02/06/2019 12:05 PM Appendix 3745-21-09 Appendix A
    ACTION: Final EXISTING DATE: 02/06/2019 12:05 PM Appendix 3745-21-09 Appendix A List of Organic Chemicals for which Paragraphs (DD) and (EE) of Rule 3745-21-09 of the Administrative Code are Applicable Organic Chemical Organic Chemical Acetal Benzaldehyde Acetaldehyde Benzamide Acetaldol Benzene Acetamide Benzenedisulfonic acid Acetanilide Benzenesulfonic acid Acetic acid Benzil Acetic Anhydride Benzilic acid Acetone Benzoic acid Acetone cyanohydrin Benzoin Acetonitrile Benzonitrile Acetophenone Benzophenone Acetyl chloride Benzotrichloride Acetylene Benzoyl chloride Acrolein Benzyl alcohol Acrylamide Benzylamine Acrylic acid Benzyl benzoate Acrylonitrile Benzyl chloride Adipic acid Benzyl dichloride Adiponitrile Biphenyl Alkyl naphthalenes Bisphenol A Allyl alcohol Bromobenzene Allyl chloride Bromonaphthalene Aminobenzoic acid Butadiene Aminoethylethanolamine 1-butene p-aminophenol n-butyl acetate Amyl acetates n-butyl acrylate Amyl alcohols n-butyl alcohol Amyl amine s-butyl alcohol Amyl chloride t-butyl alcohol Amyl mercaptans n-butylamine Amyl phenol s-butylamine Aniline t-butylamine Aniline hydrochloride p-tertbutyl benzoic acid Anisidine 1,3-butylene glycol Anisole n-butyraldehyde Anthranilic acid Butyric acid Anthraquinone Butyric anhydride Butyronitrile Caprolactam APPENDIX p(183930) pa(324943) d: (715700) ra(553210) print date: 02/06/2019 12:05 PM 3745-21-09, Appendix A 2 Carbon disulfide Cyclohexene Carbon tetrabromide Cyclohexylamine Carbon tetrachloride Cyclooctadiene Cellulose acetate Decanol Chloroacetic acid Diacetone alcohol
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • Col.V.MISSION of the EUROPEAN COMMUNITIES
    COl.V.MISSION OF THE EUROPEAN COMMUNITIES SEC(90) 1985 final· Brussels, 29 October 1990 Proposa I for a COUNCIL DIRECTIVE on the approximation of the laws of the Member States relat.ing to cosmetic products -2- EXPLANATORY UEUORANDUM 1. In the context of a people's Europe, the Commission attaches great Importance to simplifying and clarifying Community law so as to make It clearer and more accessible to the ordinary citizen, thus giving hIm new opportunItIes and the chance to make use of the spec if i c rights It gives him. This aim cannot be achieved so long as numerous provisions that have been amended several times, often QUite substantially, remain scattered, so that they must be sought partly In the original Instrument and partly In later amending ones. Considerable research work, comparing many different Instruments, Is thus needed to Identify the current rules. For this reason a consot tdatton of rules that have freQuently been amended Is essential If Community law Is to be clear and transparent. 2. In Its resolution of 26 November 1974 concerning consolidation of Its acts (1), the Council recommended that those of Its acts which have been amended several times be assembled Into a single text. It stressed that, In the Interests of legal certainty, a genuine legislative consolidation, Involving the repeal of earlier acts, should wherever possible be effected (as Is being done In this case). it conseQuently Invited the Commission to let it have proposals for consol !dation and undertook ·to examine them "as Quickly as possible, whltout bringing Into QUestion, during that consol ldatlon, the substantive solutions contained In the consol !dated texts".
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Förordning Om Ändring I Förordningen (1992:1554) Om Kontroll Av Narkotika;
    Príloha 11 k rozhodnutiu švédskych úradov vlády 22. februára 2018 § 79 1. ------IND- 2018 0079 S-- SK- ------ 20180302 --- --- PROJET Zbierka zákonov Švédska SFS Published on issued on 1 March 2018. The government hereby lays down1 that Annex 1 to the Ordinance (1992:1554) on the control of narcotic drugs2 shall read as set out below. This ordinance shall enter into force on 10 April 2018. On behalf of the Government ANNIKA STRANDHÄLL Lars Hedengran (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Ordinance reprinted as 1993:784. 1 SFS Annex 13 List of substances to be considered narcotic drugs according to the Narcotic Drugs Punishments Act Stimulants of the central nervous system ethylamphetamine (2-ethylamino-1-phenylpropane) fenethylline [1-phenyl-1-piperidyl-(2)-methyl]acetate 1-phenyl-2-butylamine N-hydroxyamphetamine propylhexedrine 4-methylthioamphetamine (4-MTA) modafinil 4-methoxy-N-methylamphetamine (PMMA, 4-MMA) 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) 4-iodo-2,5-dimethoxyphenethylamine (2C-I) 2,4,5-trimethoxyamphetamine (TMA-2) 4-methylmethcathinone (mephedrone) 4-fluoramphetamine 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one (methedrone) 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one (MDPV) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
    [Show full text]
  • Toxic, and Comatose-Fatal Blood-Plasma Concentrations (Mg/L) in Man
    Therapeutic (“normal”), toxic, and comatose-fatal blood-plasma concentrations (mg/L) in man Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Abacavir (ABC) 0.9-3.9308 appr. 1.5 [1,2] Acamprosate appr. 0.25-0.7231 1311 13-20232 [3], [4], [5] Acebutolol1 0.2-2 (0.5-1.26)1 15-20 3-11 [6], [7], [8] Acecainide see (N-Acetyl-) Procainamide Acecarbromal(um) 10-20 (sum) 25-30 Acemetacin see Indomet(h)acin Acenocoumarol 0.03-0.1197 0.1-0.15 3-11 [9], [3], [10], [11] Acetaldehyde 0-30 100-125 [10], [11] Acetaminophen see Paracetamol Acetazolamide (4-) 10-20267 25-30 2-6 (-13) [3], [12], [13], [14], [11] Acetohexamide 20-70 500 1.3 [15] Acetone (2-) 5-20 100-400; 20008 550 (6-)8-31 [11], [16], [17] Acetonitrile 0.77 32 [11] Acetyldigoxin 0.0005-0.00083 0.0025-0.003 0.005 40-70 [18], [19], [20], [21], [22], [23], [24], [25], [26], [27] 1 Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Acetylsalicylic acid (ASS, ASA) 20-2002 300-3502 (400-) 5002 3-202; 37 [28], [29], [30], [31], [32], [33], [34] Acitretin appr. 0.01-0.05112 2-46 [35], [36] Acrivastine -0.07 1-2 [8] Acyclovir 0.4-1.5203 2-583 [37], [3], [38], [39], [10] Adalimumab (TNF-antibody) appr. 5-9 146 [40] Adipiodone(-meglumine) 850-1200 0.5 [41] Äthanol see Ethanol -139 Agomelatine 0.007-0.3310 0.6311 1-2 [4] Ajmaline (0.1-) 0.53-2.21 (?) 5.58 1.3-1.6, 5-6 [3], [42] Albendazole 0.5-1.592 8-992 [43], [44], [45], [46] Albuterol see Salbutamol Alcuronium 0.3-3353 3.3±1.3 [47] Aldrin -0.0015 0.0035 50-1676 (as dieldrin) [11], [48] Alendronate (Alendronic acid) < 0.005322 -6 [49], [50], [51] Alfentanil 0.03-0.64 0.6-2.396 [52], [53], [54], [55] Alfuzosine 0.003-0.06 3-9 [8] 2 Substance Blood-plasma concentration (mg/L) t½ (h) Ref.
    [Show full text]
  • TERTIARY ACETYLENIC ALCOHOLS Compound, Ethchlorvynol (S 94) Is
    36 H. ISBELL & T. L. CHRUSCIEL TERTIARY ACETYLENIC ALCOHOLS Only two compounds are listed (Table IV). Of 152. Csarza-Perez, J., Lal, S. & Lopez, E. (1967) Med. these, methylpentynol (S 95) is a weak, short-acting Serv. J. Can., 23, No. 5, 775-778 (Addiction to hypnotic. Sales have been low and few instances chlorvynol) of abuse have been reported.155' 157 The other 153. Essig, C. F. (1964) Clin. Pharmacol., 5, 334 (Addic- compound, ethchlorvynol (S 94) is more potent and tion to sedatives and tranquilizers) instances of abuse are more frequent. There is 154. Government of the United States of America, stiong clinical documentation for abrupt withdrawal US Food and Drug Administration (1965) Back- of ethchlorvynol being followed by convulsions and ground material supplied to Advisory Committee delirium.151-154, 156 Accordingly, ethchlorvynol must on Abuse of Stimulant and Depressant Drugs, be judged to have moderate abuse potential and 27 December 1965, Washington, D.C. 155. Hitsche, B. & Herbst, A. (1967) Psychiat. et methylpentynol must, by analogy, be regarded as Neurol. (Basel), 153, 308-318 (Beobachtungen having dependence potential equivalent to that of bei Missbrauch von Methylpentinol) ethchlorvynol. 156. Hudson, H. S. & Walker, H. I. (1961) Amer. J. Psychiat., 118, 361 (Withdrawal symptoms REFERENCES following ethchlorvynol (Placidyl) dependence) 157. Marley, E. & Bartholomew, A. A. (1958) J. Neurol. 151. Cohn, C. H. (1959) Canad. med. Ass. J., 81, 733 Neurosurg. Psychiat., 21, 129-140 (Clinical (Intoxication by ethchlorvynol-Placidyl) aspects of susceptibility of methylpentol) CYCLIC ETHERS The only compound in this group is paraldehyde dogs physically dependent on barbital.
    [Show full text]
  • Decision of the Government of the Russian Federation No
    DECISION OF THE GOVERNMENT OF THE RUSSIAN FEDERATION NO. 681 OF JUNE 30, 1998 ON THE APPROVAL OF THE LIST OF NARCOTIC DRUGS, PSYCHOTROPIC SUBSTANCES AND THEIR PRECURSORS THAT SHALL BE SUBJECT TO CONTROL IN THE RUSSIAN FEDERATION In accordance with the Federal Law on Narcotic Drugs and Psychotropic Substances (Sobraniye zakonodatelstva Rossiyskoy Federatsii, 1998, No. 2, item 219) the Government of the Russian Federation resolves: To approve the annexed enumeration of narcotic drugs, psychotropic substances and their precursors that shall be subject to control in the Russian Federation. To establish that the amendment of the said enumeration shall be carried out on presentation of the Ministry of Public Health of the Russian Federation jointly with the Ministry of Internal Affairs of the Russian Federation. Chairman of the Government of the Russian Federation Sergey Kirienko Enumeration of Narcotic Drugs, Psychotropic Substances and Their Precursors That Shall Be Subject to Control in the Russian Federation (Approved by the Decision of the Government of the Russian Federation No. 681 of June 30, 1998) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Prohibited in Accordance with the Legislation of the Russian Federation and the International Treaties of the Russian Federation (List I) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Restricted and in Whose Respect Control Measures Shall Be Established in Accordance with the Legislation of
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter Et Al
    USOO9205048B2 (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter et al. (45) Date of Patent: *Dec. 8, 2015 (54) CONTROLLED RELEASE ANTIMICROBIAL (58) Field of Classification Search COMPOSITIONS AND METHODS FOR THE CPC A61 K9/0024; A61 K9/0046; A61K 31/497; TREATMENT OF OTC DSORDERS A61K 47/34 See application file for complete search history. (71) Applicants: Otonomy, Inc., San Diego, CA (US); The Regents of the University of California, Oakland, CA (US) (56) References Cited (72) Inventors: Jay Lichter, Rancho Santa Fe, CA (US); U.S. PATENT DOCUMENTS Andrew M. Trammel, Olathe, KS (US); 4,188,373 A 2, 1980 Krezanoski Fabrice Piu, San Diego, CA (US); 4,478,822 A 10, 1984 Haslam et al. Qiang Ye, San Diego, CA (US); Luis A. 4,938,763. A 7, 1990 Dunn et al. Dellamary, San Marcos, CA (US); Carl 4,968,507 A 11/1990 Zentner et al. 5,033,252 A 7, 1991 Carter Lebel, Malibu, CA (US); Jeffrey P. 5,052,558 A 10, 1991 Carter Harris, La Jolla, CA (US) 5,292,516 A 3/1994 Viegas et al. 5,323,907 A 6/1994 Kalvelage (73) Assignees: OTONOMY, INC., San Diego, CA 5,324,519 A 6/1994 Dunn et al. (US): THE REGENTS OF THE 5,421,818 A 6/1995 Arenberg UNIVERSITY OF CALIFORNLA, 5,474,529 A 12/1995 Arenberg 5,476,446 A 12/1995 Arenberg Oakland, CA (US) 5,503,848 A 4/1996 Perbellini et al. 5,702,716 A 12/1997 Dunn et al.
    [Show full text]
  • Investigations in Fish Control
    INVESTIGATIONS IN FISH CONTROL 29. Efficacy of Methylpentynol as an Anesthetic on Four Salmonids 30. Toxicity of Methylpentynol to Selected Fishes 31. Annotated Bibliography on Methylpentynol United States Department of the Interior Fish and Wildlife Service Bureau of Sport Fisheries and Wildlife INVESTIGATIONS IN FISH CONTROL Investigations in Fish Control, published by the Bureau of Sport Fisheries and Wildlife, in­ clude reports on the results of work at the Bureau's Fish Control Laboratories at La Crosse, Wis., and Warm Springs, Ga., and reports of other studies related to that work. Though each report is regarded as a separate publication, several may be issued under a single cover, for economy. Current reports in this series are (Reports 1 and 2 are in one cover.) 1. Laboratories and Methods for Screening Fish-Control Chemicals, by Robert E. Lennon and Charles R. Walker. 1964. 15 p. 2. Preliminary Observations on the Toxicity of Antimycin A to Fish and Other Aquatic Animals, by Charles R. Walker, Robert E. Lennon, and Bernard L. Berger. 1964. 18 p. (Reports 3 through 8 are in one cover.) 3. Minimum Lethal Levels of Toxaphene as a Piscicide in North Dakota Lakes, by Dale L. Henegar. 1966. 16 p. 4. Effects of Toxaphene on Plankton and Aquatic Invertebrates in North Dakota Lakes, by Robert G. Needham. 1966. 16 p. 5. Growth Rates of Yellow Perch in Two North Dakota Lakes After Population Reduction with Toxaphene, by Donald C. Warnick. 1966. 9 p. 6. Mortality of Some Species of Fish to Toxaphene at Three Temperatures, by Mahmoud Ahmed Mahdi.
    [Show full text]